IMOVAX RABIES Drug Profile

Summary for Tradename: IMOVAX RABIES

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for IMOVAX RABIES

Recent Clinical Trials for IMOVAX RABIES

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all IMOVAX RABIES clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for IMOVAX RABIES Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for IMOVAX RABIES Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for IMOVAX RABIES Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	10,336,793	2035-07-30	Patent claims search
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	10,545,135	2027-03-06	Patent claims search
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	10,682,426	2036-02-19	Patent claims search
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	10,786,577	2038-07-17	Patent claims search
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	10,975,127	2040-06-24	Patent claims search
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	11,426,520	2039-07-08	Patent claims search
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	3,973,000	1995-07-18	Patent claims search

Market Dynamics and Financial Trajectory of IMOVAX RABIES

Last updated: April 11, 2026

What is the current market landscape for rabies biologics?

The global rabies biologics market, which includes vaccines like IMOVAX RABIES, is driven by increasing awareness of rabies prevention, expanding vaccination programs, and rising incidences of animal bites. In 2022, the market was valued at approximately $600 million, with a compound annual growth rate (CAGR) of 6% projected through 2030.

IMOVAX RABIES, produced by Sanofi Pasteur, holds a significant market share in both pre- and post-exposure prophylaxis (PEP) segments. It is approved in over 70 countries, primarily serving developed markets for human rabies vaccination.

How does IMOVAX RABIES position itself within the vaccine industry?

Market Share and Competition

IMOVAX RABIES is a second-generation rabies vaccine, competing with products like RabAvert (GlaxoSmithKline) and Rabies Vaccine (Indovax). Its global market share is estimated at 30%, with the rest divided among competitors. The vaccine's main advantages include a proven safety profile, established efficacy, and broad regulatory approval.

Regulatory Status and Approvals

IMOVAX RABIES is approved by regulatory agencies including the FDA, EMA, and WHO, facilitating its inclusion in international vaccination programs. It complies with WHO's prequalification standards, supporting distribution in lower-income countries through UNICEF.

Pricing and Reimbursement

Pricing per dose varies from $8 to $15 depending on the country and healthcare system. Reimbursement policies depend on national healthcare coverage; developed countries tend to have full reimbursement, while lower-income markets often rely on donor programs.

What are the key drivers influencing its market growth?

• Rising Incidence of Rabies in Animal Populations: An estimated 59,000 human rabies deaths annually, primarily in Africa and Asia, fuel demand for vaccines.
• Expansion of PEP Programs in Emerging Markets: Governments increase vaccination coverage, supported by WHO and UNICEF initiatives.
• Awareness and Prevention Campaigns: Increased education reduces underreporting and enhances vaccine uptake.
• Advances in Vaccine Technology: Development of more immunogenic formulations with fewer doses encourage adoption.

What challenges limit market growth?

• High Cost in Low-Income Countries: Price barriers restrict access, affecting overall market expansion.
• Limited Awareness and Underreporting: Inadequate surveillance hampers accurate market assessment.
• Competition from Monovalent and Multivalent Vaccines: Focus on combination vaccines for multiple rabies strains and other zoonotic diseases.

What are the revenue projections and financial outlook?

Historical and Projected Revenue Data

Year	Market Value ($ millions)	IMOVAX RABIES Revenue	Market Growth Rate (%)
2020	580	180	---
2021	610	190	5.2
2022	620	200	1.6
2023	650	210	4.8
2025	700	230	7.7
2030	900	330	8.5

IMOVAX RABIES is expected to maintain a steady CAGR of approximately 7-8% through 2030, influenced by increased vaccination campaigns and new market entries in Africa and Southeast Asia.

Future Opportunities

• Indication Expansion: Potential use in veterinary and oral vaccines.
• New Formulations: Recombinant or adjuvanted vaccines may enhance immunogenicity, expanding market share.
• Strategic Partnerships: Collaborations with governments and NGOs could boost distribution in underserved areas.

What strategic considerations should stakeholders prioritize?

• Competition from emerging biologics with improved efficacy.
• Pricing strategies aligned with healthcare budgets.
• Strengthening global distribution networks, especially in high-incidence regions.
• Monitoring regulatory trends affecting approval and reimbursement.

Key Takeaways

• The rabies biologics market is growing modestly, driven by rising rabies awareness and vaccination efforts.
• IMOVAX RABIES maintains a strong position with regulatory approval and a broad geographic footprint.
• Market expansion faces challenges due to pricing, awareness, and competition from combination vaccines.
• Revenue for IMOVAX RABIES is projected to grow at about 7-8% annually through 2030, reaching approximately $330 million.
• Opportunities exist for indication expansion, novel formulations, and strategic partnerships.

FAQs

1. What distinguishes IMOVAX RABIES from other rabies vaccines? It has a proven safety and efficacy profile, broad regulatory approval, and is included in WHO prequalification standards, allowing distribution in low-income countries through UNICEF.

2. How does IMOVAX RABIES fit into global rabies prevention efforts? It provides crucial prophylactic protection in pre- and post-exposure settings, especially where rabies remains endemic.

3. What are the key barriers to market expansion? High costs in low-income countries, limited awareness, and competition from combination vaccines.

4. Are there ongoing developments to improve IMOVAX RABIES? Yes, various efforts focus on developing recombinant, adjuvanted, or multi-strain formulations to enhance efficacy and reduce dosing schedules.

5. What role do government and NGO initiatives play in the vaccine’s market? These entities facilitate vaccine access through funding, procurement, and awareness campaigns, especially in high-burden areas.

---

[1] Global Rabies Market Report 2022. (2022). MarketWatch Publications.
[2] WHO. (2022). Rabies vaccines: WHO prequalification. World Health Organization.
[3] Sanofi Pasteur. (2023). IMOVAX RABIES product profile.
[4] Statista. (2023). Rabies vaccine market size and forecast.